Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Interim timepoints not in PM
-
In our PM, the data for an endpoint are reported only for baseline and the final timepoint (example, Week 52). There is no mention of interim timepoints in the PM. However, the trial publication contains a chart showing the data for the interim time points (example, every 2 weeks) - would it be acceptable to include these charts, with the interim time points, in a branded, HCP-directed piece?
-
Hello @kbernard
Providing the published study meets PAAB requirements as a standalone trial, as a general rule of thumb, if the timepoints are predefined, tested for statistical significance, and are directionally consistent with the primary endpoint, it would be acceptable to present them in the piece in a non-selective and complete manner.
